Jefferies stays Buy on Enanta Pharmaceuticals (ENTA) as co announces oral arguments for PFE patent case

March 31, 2026 4:52 PM

Jefferies analyst Akash Tewari reiterated a Buy rating and $20.00 price target on Enanta Pharmaceuticals (NASDAQ: ENTA)The analyst commented, "ENTA ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found